Cheryl Scott
Known title: DirectorCIK: 0001656979
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Evolent Health Faces Critique, Wins Telephonic Interpretation Contract. Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.
Transaction History
| PGNY | ▲ Buy | Option Exercise | 14,667 | $191K | 6/1/2026 | View on chart |
| PGNY | ▼ Sell | Tax Withholding | 7,228 | $191K | 6/1/2026 | View on chart |
| PGNY | ▼ Sell | Open Market | 7,439 | $196K | 6/1/2026 | View on chart |
| PGNY | ▲ Buy | Grant | 5,660 | $0 | 5/21/2026 | View on chart |
| PGNY | ▼ Sell | Open Market | 2,675 | $59K | 6/11/2025 | View on chart |
| EVH | ▲ Buy | Grant | 21,979 | $0 | 6/5/2025 | View on chart |
| PGNY | ▲ Buy | Grant | 6,689 | $0 | 5/22/2025 | View on chart |
| PGNY | ▼ Sell | Open Market | 1,462 | $42K | 6/28/2024 | View on chart |
| EVH | ▲ Buy | Grant | 7,709 | $0 | 6/6/2024 | View on chart |
| PGNY | ▲ Buy | Grant | 5,147 | $0 | 5/23/2024 | View on chart |
| PGNY | ▼ Sell | Gift | 30 | $0 | 11/20/2023 | View on chart |
| PGNY | ▼ Sell | Gift | 3,301 | $0 | 11/20/2023 | View on chart |
| PGNY | ▼ Sell | Open Market | 1,170 | $44K | 6/27/2023 | View on chart |
| EVH | ▼ Sell | Open Market | 2,365 | $71K | 6/14/2023 | View on chart |
| EVH | ▲ Buy | Grant | 5,049 | $0 | 6/8/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 3,654 | $0 | 5/24/2023 | View on chart |
| PGNY | ▼ Sell | Open Market | 850 | $35K | 11/7/2022 | View on chart |
| PGNY | ▲ Buy | Grant | 2,900 | $0 | 10/24/2022 | View on chart |
| EVH | ▼ Sell | Open Market | 3,100 | $114K | 8/31/2022 | View on chart |
| EVH | ▲ Buy | Grant | 5,564 | $0 | 6/9/2022 | View on chart |
| PGNY | ▼ Sell | Open Market | 2,000 | $133K | 11/8/2021 | View on chart |
| PGNY | ▲ Buy | Grant | 2,210 | $0 | 10/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace
Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.